RxDoctor Payments Data

Erika Potts

Family · Clovis, NMNPI 1568634491

Payments from drug & device makers

$392in general payments, 2019–2025

Across 23 payments — averaging $17.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$92
  • Mylan Specialty L.p.$82
  • Lilly USA, LLC$66
  • Johnson & Johnson$40
  • Amarin Pharma, Inc.$24
  • Novartis$24
  • plus $65 from 4 others

What the payments were for

  • Food & beverage$392100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$392 in reported general payments places this provider in the 60th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$133,318
Medicare patients
208
Services billed
3,122

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin38$44,817
MounjaroTirzepatide27$35,894
OzempicSemaglutide30$35,159
JanuviaSitagliptin Phosphate24$23,573
TrulicityDulaglutide15$19,503
Spiriva RespimatTiotropium Bromide16$11,162
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog25$9,500
FarxigaDapagliflozin Propanediol14$8,796
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$4,303
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$4,169
Atorvastatin Calcium240$1,854
Levothyroxine Sodium229$1,763
Pregabalin24$1,528
Lisinopril234$1,365
Duloxetine Hcl51$1,327

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$66$55,39742 claims
Novo NordiskOzempic$92$35,15930 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,080 family providers in New Mexico.

Other family in Clovis

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →